Literature DB >> 15734849

Functional and molecular defects of pancreatic islets in human type 2 diabetes.

Silvia Del Guerra1, Roberto Lupi, Lorella Marselli, Matilde Masini, Marco Bugliani, Simone Sbrana, Scilla Torri, Maria Pollera, Ugo Boggi, Franco Mosca, Stefano Del Prato, Piero Marchetti.   

Abstract

To shed further light on the primary alterations of insulin secretion in type 2 diabetes and the possible mechanisms involved, we studied several functional and molecular properties of islets isolated from the pancreata of 13 type 2 diabetic and 13 matched nondiabetic cadaveric organ donors. Glucose-stimulated insulin secretion from type 2 diabetic islets was significantly lower than from control islets, whereas arginine- and glibenclamide-stimulated insulin release was less markedly affected. The defects were accompanied by reduced mRNA expression of GLUT1 and -2 and glucokinase and by diminished glucose oxidation. In addition, AMP-activated protein kinase activation was reduced. Furthermore, the expression of insulin was decreased, and that of pancreatic duodenal homeobox-1 (PDX-1) and forkhead box O1 (Foxo-1) was increased. Nitrotyrosine and 8-hydroxy-2'-deoxyguanosine concentrations, markers of oxidative stress, were significantly higher in type 2 diabetic than control islets, and they were correlated with the degree of glucose-stimulated insulin release impairment. Accordingly, 24-h exposure to glutathione significantly improved glucose-stimulated insulin release and decreased nitrotyrosine concentration, with partial recovery of insulin mRNA expression. These results provide direct evidence that the defects of insulin secretion in type 2 diabetic islets are associated with multiple islet cell alterations. Most importantly, the current study shows that the functional impairment of type 2 diabetic islets can be, at least in part, reversible. In this regard, it is suggested that reducing islet cell oxidative stress is a potential target of human type 2 diabetes therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734849     DOI: 10.2337/diabetes.54.3.727

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  173 in total

1.  Injectable hydrogel microbeads for fluorescence-based in vivo continuous glucose monitoring.

Authors:  Hideaki Shibata; Yun Jung Heo; Teru Okitsu; Yukiko Matsunaga; Tetsuro Kawanishi; Shoji Takeuchi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

Authors:  Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-27       Impact factor: 4.310

3.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

Authors:  Valeriya Lyssenko; Roberto Lupi; Piero Marchetti; Silvia Del Guerra; Marju Orho-Melander; Peter Almgren; Marketa Sjögren; Charlotte Ling; Karl-Fredrik Eriksson; Asa-Linda Lethagen; Rita Mancarella; Göran Berglund; Tiinamaija Tuomi; Peter Nilsson; Stefano Del Prato; Leif Groop
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Ameliorative Effects of Oral Glucosamine on Insulin Resistance and Pancreatic Tissue Damage in Experimental Wistar rats on a High-fat Diet.

Authors:  Cornelio Barrientos; Angélica Pérez; Jorge Vázquez
Journal:  Comp Med       Date:  2021-06-03       Impact factor: 0.982

Review 5.  Glucolipotoxicity: fuel excess and beta-cell dysfunction.

Authors:  Vincent Poitout; R Paul Robertson
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

Review 6.  The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

Authors:  S E Kahn; S Zraika; K M Utzschneider; R L Hull
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

7.  Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells.

Authors:  Mourad Ferdaoussi; Xiaoqing Dai; Mette V Jensen; Runsheng Wang; Brett S Peterson; Chao Huang; Olga Ilkayeva; Nancy Smith; Nathanael Miller; Catherine Hajmrle; Aliya F Spigelman; Robert C Wright; Gregory Plummer; Kunimasa Suzuki; James P Mackay; Martijn van de Bunt; Anna L Gloyn; Terence E Ryan; Lisa D Norquay; M Julia Brosnan; Jeff K Trimmer; Timothy P Rolph; Richard G Kibbey; Jocelyn E Manning Fox; William F Colmers; Orian S Shirihai; P Darrell Neufer; Edward T H Yeh; Christopher B Newgard; Patrick E MacDonald
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

8.  Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.

Authors:  D J Baker; A M Atkinson; G P Wilkinson; G J Coope; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  Perilipin is present in islets of Langerhans and protects against lipotoxicity when overexpressed in the beta-cell line INS-1.

Authors:  Jörgen Borg; Cecilia Klint; Nils Wierup; Kristoffer Ström; Sara Larsson; Frank Sundler; Roberto Lupi; Piero Marchetti; Guoheng Xu; Alan Kimmel; Constantine Londos; Cecilia Holm
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

10.  Chronic Exposure to Proline Causes Aminoacidotoxicity and Impaired Beta-Cell Function: Studies In Vitro.

Authors:  Zhenping Liu; Per B Jeppesen; Søren Gregersen; Lotte Bach Larsen; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.